Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials

Uli A. Liberman, M. C. Hochberg, P. Geusens, A. Shah, J. Lin, A. Chattopadhyay, P. D. Ross

Research output: Contribution to journalArticlepeer-review

Abstract

A number of antiresorptive agents reduce the risk of vertebral fractures, but few have shown consistent effects on hip and other non-spine fractures. Meta-analysis provides a more precise estimate than individual trials when results are consistent across pooled trials. Earlier meta-analyses summarised the results for vertebral and non-spine fractures. New data have emerged for hormone therapy (HT), alendronate (ALN), risedronate (RIS) and ibandronate (IBN). We surveyed recent reports of randomised, placebo-controlled trials with non-spine and/or hip fracture data, and used meta-analysis where appropriate to test for heterogeneity and derive pooled estimates. The magnitude of effect on hip fracture appears to be similar to that for non-spine fracture for each drug, but differs among drugs. Based on the current data, ALN reduces the risk of hip and non-spine fracture by 49-55%, HT by 25-36% and RIS by 26-27%. There is insufficient and/or inconsistent evidence of an effect on these fractures for IBN, calcitonin and raloxifene.

Original languageEnglish
Pages (from-to)1394-1400
Number of pages7
JournalInternational Journal of Clinical Practice
Volume60
Issue number11
DOIs
StatePublished - Nov 2006
Externally publishedYes

Keywords

  • Alendronate
  • Antiresorptive therapy
  • Fracture
  • Hormone therapy
  • Ibandronate
  • Osteoporosis
  • Raloxifene
  • Risedronate

Fingerprint

Dive into the research topics of 'Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials'. Together they form a unique fingerprint.

Cite this